The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2017 | Results of the GMMG PERSPECTIVE trial: triple regimen for R/R multiple myeloma
Is the addition of cyclophosphamide to pomalidomide (Pom) and dexamethasone (Dex) treatment more effective at inducing a deeper and more durable remission for patients with relapsed and/or refractory multiple myeloma (MM) compared to Pom and Dex alone? Speaking from the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition, held in Atlanta, GA, Katja Weisel, MD, of University of Tübingen, Tübingen, Germany, discusses the exciting results from the GMMG PERSPECTIVE trial (NCT02046915), which investigated this question.
